首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >A Systems Pharmacology-Based Study of the Molecular Mechanisms of San Cao Decoction for Treating Hypertension
【2h】

A Systems Pharmacology-Based Study of the Molecular Mechanisms of San Cao Decoction for Treating Hypertension

机译:基于系统药理的三草汤治疗高血压分子机制的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Traditional Chinese medicine (TCM) has a longstanding history and has gained widespread clinical applications. San Cao Decoction (SCD) is an experience prescription first formulated by Prof. Duzhou Liu. We previously demonstrated its antihypertensive effects; however, to systematically explain the underlying mechanisms of action, we employed a systems pharmacology approach for pharmacokinetic screening and target prediction by constructing protein-protein interaction networks of hypertension-related and putative SCD-related targets, and Database for Annotation, Visualization, and Integrated Discovery enrichment analysis. We identified 123 active compounds in SCD and 116 hypertension-related targets. Furthermore, the enrichment analysis of the drug-target network showed that SCD acts in a multidimensional manner to regulate PI3K-Akt-endothelial nitric oxide synthase signaling to maintain blood pressure. Our results highlighted the molecular mechanisms of antihypertensive actions of medicinal herbs at a systematic level.
机译:中药(TCM)历史悠久,已获得广泛的临床应用。三草汤(SCD)是刘笃舟教授首先制定的经验处方。我们之前已经证明了它的降压作用。但是,为了系统地解释其潜在的作用机理,我们通过构建高血压相关和推定的SCD相关靶标的蛋白质-蛋白质相互作用网络以及注释,可视化和集成数据库,采用了系统药理学方法进行药代动力学筛选和靶标预测发现富集分析。我们在SCD和116个与高血压相关的靶标中鉴定了123种活性化合物。此外,对药物靶标网络的富集分析表明SCD以多维方式调节PI3K-Akt-内皮一氧化氮合酶信号传导以维持血压。我们的结果在系统的水平上突出了中药抗高血压作用的分子机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号